Interferon and lamivudine combination therapy versus lamivudine monotherapy for hepatitis B e antigen-negative hepatitis B treatment: A meta-analysis of randomized controlled trials

Hepatobiliary and Pancreatic Diseases International

Volumn 9, Issue 5, 2010, Pages 462-472

  Shi, Yu ^a   Wu, Yi Hua ^a   Shu, Zhe Yue ^a   Zhang, Wan Jun ^b   Yang, Jun ^a   Chen, Zhi ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chronic hepatitis B; Combination therapy; HBeAg negative; Interferon alpha; Lamivudine; Monotherapy

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; HEPATITIS B; HUMAN; META ANALYSIS; MONOTHERAPY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; DRUG CARRIERS; DRUG THERAPY, COMBINATION; HEPATITIS B; HEPATITIS B E ANTIGENS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LAMIVUDINE; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 78249237601     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc 2007;82:967-975.
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337: 1733-1745.
3. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359:1486-1500.
4. Taylor BC, Yuan JM, Shamliyan TA, Shaukat A, Kane RL, et al. Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: A systematic review of evidence. Hepatology 2009;49:S85-95.
5. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6:1315-1341.
6. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
7. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004; 116:829-834.
8. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35:1522-1527.
9. Hui CK, Leung N, Shek TW, Yao H, Lee WK, Lai JY, et al. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology 2007;46:690-698.
10. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
11. Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009 Jun 24. [Epud ahead of print]
12. Keeffe EB. Hepatitis B: explosion of new knowledge. Gastroenterology 2007;133:1718-1721.
13. Ahmad N, Alam S, Mustafa G, Adnan AB, Baig RH, Khan M. e-antigen-negative chronic hepatitis B in Bangladesh. Hepatobiliary Pancreat Dis Int 2008;7:379-382.
14. Shi YH, Shi CH. Molecular characteristics and stages of chronic hepatitis B virus infection. World J Gastroenterol 2009;15:3099-3105.
15. Yang CG, Yu YC, Chen JJ, Sun J, Guo YB, Luo KX, et al. A comparison of clinical and virological characteristics of 1686 cases of HBeAg-negative and HBeAg-positive chronic hepatitis B. Zhonghua Nei Ke Za Zhi 2005;44:648-651.
16. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigennegative chronic hepatitis B. Hepatology 2001;34:617-624.
17. Zhao DY, Qin YQ, Tang XM, Liu GZ, Zheng W, Nong HR, et al. Relationship among pathological changes in Liver tissues and level of serum HBV DNA, HBeAg and ALT of 194 patients with chronic hepatitis B. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2007;21:35-37.
18. Zhang FK. Interferon-alfa in the treatment of chronic hepatitis B. Hepatobiliary Pancreat Dis Int 2004;3:337-340.
19. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45:1056-1075.
20. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-1263.
21. Kaymakoglu S, Danalioglu A, Demir K, Karaca C, Akyuz F, Onel D, et al. Long-term results of interferon alpha monotherapy in patients with HBeAg-negative chronic hepatitis B. Dig Dis Sci 2007;52:727-731.
22. Vassiliadis TG, Giouleme O, Koumerkeridis G, Koumaras H, Tziomalos K, Patsiaoura K, et al. Adefovir plus lamivudine are more effective than adefovir alone in lamivudineresistant HBeAg- chronic hepatitis B patients: a 4-year study. J Gastroenterol Hepatol 2010;25:54-60.
23. Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology 2008;47:447-454.
24. Scotto G, Palumbo E, Fazio V, Cibelli DC, Saracino A, Angarano G. Efficacy and tolerability of lamivudine alone versus lamivudine plus alpha-interferon for treatment of chronic active hepatitis B in patients with a precore-mutant variant. Infez Med 2006;14:145-151.
25. Akyuz F, Kaymakoglu S, Demir K, Aksoy N, Karaca C, Danalioglu A, et al. Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy. Acta Gastroenterol Belg 2007;70:20-24. (Pubitemid 46597997)
26. Shi M, Wang RS, Zhang H, Zhu YF, Han B, Zhang Y, et al. Sequential treatment with lamivudine and interferonalpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. J Antimicrob Chemother 2006;58:1031-1035.
27. Akarca US, Ersoz G, Gunsar F, Karasu Z, Saritas E, Yuce G, et al. Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B. Antivir Ther 2004;9:325-334.
28. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1: 431-435.
29. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
30. Yurdaydin C, Bozkaya H, Cetinkaya H, Sahin T, Karaoguz D, Törüner M, et al. Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B. J Viral Hepat 2005;12:262-268. (Pubitemid 40638033)
31. Santantonio T, Niro GA, Sinisi E, Leandro G, Insalata M, Guastadisegni A, et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002;36:799-804.
32. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-1217.
33. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigennegative chronic hepatitis B using transient elastography. Am J Gastroenterol 2008;103:3071-3081.
34. Economou M, Manolakopoulos S, Trikalinos TA, Filis S, Bethanis S, Tzourmakliotis D, et al. Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J Gastroenterol 2005;11:5882-5887.
35. Jaboli MF, Fabbri C, Liva S, Azzaroli F, Nigro G, Giovanelli S, et al. Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: results of an open, controlled trial. World J Gastroenterol 2003;9:1491-1495.
36. Zarski JP, Marcellin P, Leroy V, Trepo C, Samuel D, Ganne- Carrie N, et al. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J Hepatol 2006;45:355-360.
37. Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouillères O, Carbonell N, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 2001;34:573-577.
38. Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 2007;13:125-140.
39. Terrault NA. Benefits and risks of combination therapy for hepatitis B. Hepatology 2009;49:S122-128.
40. Sarin SK, Kumar M, Hissar S, Sharma BC. Combination of pegylated interferon and lamivudine for patients with chronic hepatitis B who have failed treatment. Hepatobiliary Pancreat Dis Int 2006;5:374-380.
41. Sarin SK, Sood A, Kumar M, Arora A, Amrapurkar D, Sharma BC, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007; 102:96-104.
42. Papadopoulos V, Protopapas A, Tsianos E, Mimidis K. Threeyear follow-up of pegylated interferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAgnegative chronic hepatitis B. Scand J Gastroenterol 2009;44: 1021-1022.
43. Bowden S, Shaw T. Hepatitis B: the case for combination therapy. Curr Opin Investig Drugs 2009;10:795-803.
44. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991;88:8495-8499.
45. Rang A, Günther S, Will H. Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells. J Hepatol 1999;31:791-799.
46. Gordien E, Rosmorduc O, Peltekian C, Garreau F, Bréchot C, Kremsdorf D. Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J Virol 2001;75:2684-2691.
47. Peltekian C, Gordien E, Garreau F, Meas-Yedid V, Soussan P, Willams V, et al. Human MxA protein participates to the interferon-related inhibition of hepatitis B virus replication in female transgenic mice. J Hepatol 2005;43:965-972.
48. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102:968-975.
49. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001;33:963-971.
50. Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Missale G, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003;39:595-605.
51. García Buey L, González Mateos F, Moreno Otero R. Interferon in hepatitis B. Enferm Infecc Microbiol Clin 2008; 26:19-31.
52. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009;49:S103-111.
53. Buster EH, Schalm SW, Janssen HL. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. Best Pract Res Clin Gastroenterol 2008;22:1093-1108.
54. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-2788.
55. Gauthier J, Bourne EJ, Lutz MW, Crowther LM, Dienstag JL, Brown NA, et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999;180: 1757-1762.
56. Gauthier J, Bourne EJ, Lutz MW, Crowther LM, Dienstag JL, Brown NA, et al. Baseline characteristics and early ontreatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009; 51:11-20.
57. Reijnders JG, Leemans WF, Hansen BE, Pas SD, de Man RA, Schutten M, et al. On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks. J Viral Hepat 2009;16:113-120.
58. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycolconjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001;12:195-202.
59. Keam SJ, Cvetkovic RS. Spotlight on peginterferon-alpha- 2a (40 kD) plus ribavirin in the management of chronic hepatitis C mono-infection. BioDrugs 2009;23:63-68.
60. Keam SJ, Cvetkovic RS. Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection. Drugs 2008;68:1273-1317.
61. Zhao H, Si CW, Wei L, Wan MB, Ying YK, Hou JL, et al. A multicenter, randomized, open-label study of the safety and effectiveness of pegylated interferon alpha 2b and interferon alpha 2b in treating HBeAg positive chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 2006;14:323-326.